Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
- 23 March 2006
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (5), 873-883
- https://doi.org/10.1185/030079906x104696
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MetS). There is no established treatment for NAFLD. To evaluate a multifactorial intervention in the treatment of NAFLD. A prospective, open-label, randomised study in non-diabetic patients (n = 186) with MetS (follow-up: 54 weeks). All patients had both biochemical and ultrasonographic evidence of NAFLD at baseline. Other causes of liver disease were excluded. Patients received lifestyle advice and treatment for hypertension (mainly inhibitors of the renin-angiotensin system), impaired fasting glucose (metformin), obesity (orlistat) and dyslipidaemia [randomly allocated to atorvastatin 20 mg/day (n = 63) or micronised fenofibrate 200 mg/day (n = 62) or both drugs (n = 61)]. Liver ultrasonography was assessed at baseline and at the end of the study. At the end of treatment, 67% of patients on atorvastatin, 42% on fenofibrate and 70% on combination treatment no longer had biochemical plus ultrasonographic evidence of NAFLD (p < 0.05 vs. baseline for all comparisons). The percentage of patients who no longer had evidence of NAFLD was significantly higher (p < 0.009) in the atorvastatin and combination groups compared with the fenofibrate group. This effect was independently related to drug treatment, as well as to reductions in high-sensitivity C-reactive protein, waist circumference, body weight, triglycerides, low-density lipoprotein-cholesterol, total cholesterol, systolic blood pressure and glucose. Four patients discontinued treatment because of adverse effects. Multifactorial intervention in MetS patients with both biochemical and ultrasonographic evidence of NAFLD offsets surrogate markers of NAFLD (i.e. elevated aminotransferase plus echogenic liver).Keywords
This publication has 43 references indexed in Scilit:
- Targeting vascular risk in patients with metabolic syndrome but without diabetesMetabolism, 2005
- Nonalcoholic fatty liver disease and the metabolic syndromeCurrent Opinion in Lipidology, 2005
- Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver diseaseJCI Insight, 2005
- Nonalcoholic Fatty Liver Disease Is Associated With Carotid AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of lifeGut, 2004
- Epidemic Obesity and the Metabolic SyndromeCirculation, 2003
- The utility of radiological imaging in nonalcoholic fatty liver diseaseGastroenterology, 2002
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Therapeutic effects of restricted diet and exercise in obese patients with fatty liverJournal of Hepatology, 1997
- Ultrasound scanning in the detection of hepatic fibrosis and steatosis.BMJ, 1986